Last updated: February 25, 2026
What is NDC 60505-4643?
The NDC 60505-4643 corresponds to a specific prescription drug, identified by the National Drug Code (NDC) system used in the United States. NDC 60505-4643 is associated with Rylaze (asparaginase erwinia chrysanthemi origin), used in the treatment of acute lymphoblastic leukemia (ALL), specifically for patients allergic to E. coli-derived asparaginase.
Market Overview
Therapeutic Market Position
Rylaze is part of the asparaginase class, with limited market competition due to its specialty indication and manufacturing constraints. Its primary competitors include E. coli-derived asparaginase brands like Elspar and Oncaspar.
Market Size & Revenue Potential
In 2022, the US market for asparaginase products generated approximately $300 million in sales. Rylaze, launched in 2021, holds a substantial share of this niche, with an estimated revenue of around $150 million in 2022, accounting for roughly 50% of the segment, driven by its use in both pediatric and adult oncology.
Patient Population
Approximately 6,000 new cases of pediatric ALL are diagnosed annually in the US. About 10% to 15% of these patients require asparaginase therapy due to hypersensitivity to E. coli-derived formulations, positioning Rylaze as the preferred alternative.
Regulatory Status & Market Access
- FDA Approval: September 2021.
- Pricing & Reimbursement: Pricing aligned with similar niche oncology drugs, with commercial list prices around $27,000 per vial (average dose). Insurance coverage is generally favorable given the drug’s clinical necessity.
Price Projections
Current Pricing Structure
- List Price: ~$27,000 per vial.
- Average Treatment Course: 3-4 vials, with total costs reaching $81,000–$108,000 per patient.
- Reimbursement: Coverage predominantly from private insurers and government programs, with negotiated discounts reducing net price.
Short-Term Projections (2023–2025)
- Price Stability: List prices are likely to remain stable due to limited competition and high demand.
- Reimbursement Trends: Slight declines in net prices expected due to increased payer negotiations and volume-based discounts.
- Market Penetration: Expected to reach over 70% utilization among hypersensitive ALL patients within 2 years of launch.
Long-Term Projections (2026–2030)
- Pricing Trends: Expect minor price increases aligned with inflation and R&D recovery costs. List price growth estimated at 2-3% annually.
- Market Expansion: Potential extension of approved indications could increase patient access, raising annual revenue to approximately $200 million by 2030.
- Competitive Threats: Introduction of biosimilars or alternative formulations could pressure prices downward post-2028.
Competitive Landscape Impact
The emergence of biosimilars and new formulations could reduce prices by 15-30% over the next 5 years, depending on regulatory and patent challenges. Current proprietary protections are expected to last until 2030, delaying biosimilar entry.
Risks and Opportunities
- Pricing Risks: Regulatory interventions to cap prices or promote biosimilar substitution.
- Market Opportunities: Expanding use to adult ALL, where hypersensitivity is also prevalent.
- Manufacturing Constraints: Ensuring sufficient supply to meet rising demand.
Key Data Summary
| Parameter |
2022 Data |
Projections (2023–2030) |
| US Market Size |
~$150 million |
$150–200 million |
| Average List Price |
~$27,000 per vial |
Stable with 2-3% annual increase |
| Annual Revenue (US) |
~$150 million |
$150–200 million (by 2030) |
| Price Discount from Payers |
10–20% negotiated discounts |
Slight decline in net price over time |
Conclusions
Rylaze maintains a stable pricing trajectory driven by its limited competition, high demand, and niche role. The market is poised to grow modestly, with potential pressure from biosimilars. Longer-term, increased indication approvals and expanded access could boost sales, but regulatory and patent developments will influence price stability.
Key Takeaways
- NDC 60505-4643 is associated with Rylaze, a key therapy for hypersensitive ALL cases.
- Market size in the US is roughly $150 million annually, with margins supported by high drug prices.
- Price projections indicate stability in list prices, with slight declines expected in net prices due to payer negotiations.
- Market growth depends on expanding use and biosimilar competition starting around 2028.
- Price sensitivity is influenced by regulatory pressures and manufacturer capacity.
FAQs
1. Will Rylaze’s price increase significantly in the next five years?
No. List prices are expected to grow 2-3% annually, aligned with inflation, with net prices slightly declining due to negotiated discounts.
2. How might biosimilar entry impact Rylaze's pricing?
Introduction of biosimilars could reduce prices by approximately 15-30%, likely after patent expiration around 2030.
3. What is the primary driver of Rylaze’s market demand?
The need for hypersensitivity management in pediatric ALL patients, which accounts for a substantial share of the overall leukemia treatment market.
4. Are there geographic limitations to Rylaze’s market?
Yes. Currently, Rylaze’s approval is limited to the US and select markets; global expansion may alter market size and pricing.
5. What factors could threaten Rylaze’s market position?
Regulatory price controls, biosimilar competition, and manufacturing constraints could reduce profitability or market share.
References
- U.S. Food and Drug Administration. (2021). Rylaze (asparaginase erwinia chrysanthemi).
- IQVIA. (2022). US pharmaceutical market data.
- EvaluatePharma. (2022). Oncology drug market analysis.
- Centers for Disease Control and Prevention. (2022). Childhood leukemia statistics.
- Kaiser Family Foundation. (2022). Healthcare coverage and reimbursement data.
